138 related articles for article (PubMed ID: 20088932)
1. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
Qin L; D'Alessandro-Gabazza CN; Aoki S; Gil-Bernabe P; Yano Y; Takagi T; Boveda-Ruiz D; Ramirez Marmol AY; San Martin Montenegro VT; Toda M; Miyake Y; Taguchi O; Takei Y; Morser J; Gabazza EC
J Thromb Haemost; 2010 Apr; 8(4):808-16. PubMed ID: 20088932
[TBL] [Abstract][Full Text] [Related]
2. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
Voelkel NF; Tuder RM; Bridges J; Arend WP
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
[TBL] [Abstract][Full Text] [Related]
4. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma.
Fujiwara A; Taguchi O; Takagi T; D'Alessandro-Gabazza CN; Boveda-Ruiz D; Toda M; Yasukawa A; Matsushima Y; Miyake Y; Kobayashi H; Kobayashi T; Gil-Bernabe P; Naito M; Yoshida M; Morser J; Takei Y; Gabazza EC
Lung; 2012 Apr; 190(2):189-98. PubMed ID: 22037793
[TBL] [Abstract][Full Text] [Related]
5. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice.
Aliotta JM; Pereira M; Wen S; Dooner MS; Del Tatto M; Papa E; Goldberg LR; Baird GL; Ventetuolo CE; Quesenberry PJ; Klinger JR
Cardiovasc Res; 2016 Jun; 110(3):319-30. PubMed ID: 26980205
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
7. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
[TBL] [Abstract][Full Text] [Related]
9. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
10. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
Renckens R; Roelofs JJ; ter Horst SA; van 't Veer C; Havik SR; Florquin S; Wagenaar GT; Meijers JC; van der Poll T
J Immunol; 2005 Nov; 175(10):6764-71. PubMed ID: 16272333
[TBL] [Abstract][Full Text] [Related]
11. Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice.
Aliotta JM; Pereira M; Amaral A; Sorokina A; Igbinoba Z; Hasslinger A; El-Bizri R; Rounds SI; Quesenberry PJ; Klinger JR
Cardiovasc Res; 2013 Dec; 100(3):354-62. PubMed ID: 23867631
[TBL] [Abstract][Full Text] [Related]
12. Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy.
Umar S; Partow-Navid R; Ruffenach G; Iorga A; Moazeni S; Eghbali M
Biol Sex Differ; 2017; 8():9. PubMed ID: 28344760
[TBL] [Abstract][Full Text] [Related]
13. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system.
Naito M; Taguchi O; Kobayashi T; Takagi T; D'Alessandro-Gabazza CN; Matsushima Y; Boveda-Ruiz D; Gil-Bernabe P; Matsumoto T; Chelakkot-Govindalayathil AL; Toda M; Yasukawa A; Hataji O; Morser J; Takei Y; Gabazza EC
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):646-53. PubMed ID: 23721130
[TBL] [Abstract][Full Text] [Related]
14. Protective role of protein C inhibitor in monocrotaline-induced pulmonary hypertension.
Nishii Y; Gabazza EC; Fujimoto H; Nakahara H; Takagi T; Bruno N; D'Alessandro-Gabazza CN; Maruyama J; Maruyama K; Hayashi T; Adachi Y; Suzuki K; Taguchi O
J Thromb Haemost; 2006 Nov; 4(11):2331-9. PubMed ID: 17059470
[TBL] [Abstract][Full Text] [Related]
15. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.
Tofovic SP; Salah EM; Mady HH; Jackson EK; Melhem MF
J Cardiovasc Pharmacol; 2005 Oct; 46(4):430-7. PubMed ID: 16160593
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
Wang Y; Hu F; Mu X; Wu F; Yang D; Zheng G; Sun X; Gong K; Zhang Z
Biorheology; 2016 Jan; 53(1):13-22. PubMed ID: 26889655
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
Mook-Kanamori BB; Valls Serón M; Geldhoff M; Havik SR; van der Ende A; Baas F; van der Poll T; Meijers JC; P Morgan B; Brouwer MC; van de Beek D
J Thromb Haemost; 2015 Nov; 13(11):2076-86. PubMed ID: 26340319
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Nagashima M; Yin ZF; Zhao L; White K; Zhu Y; Lasky N; Halks-Miller M; Broze GJ; Fay WP; Morser J
J Clin Invest; 2002 Jan; 109(1):101-10. PubMed ID: 11781355
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling.
Fu J; Chen YF; Zhao X; Creighton JR; Guo Y; Hage FG; Oparil S; Xing DD
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1539-47. PubMed ID: 24790141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
